LifeMD (LFMD) has wrapped up FY 2025 with Q4 revenue of about US$46.9 million and basic EPS of around a US$0.04 loss, alongside trailing twelve month revenue of roughly US$194.1 million and basic EPS of about a US$0.32 loss. Over the past few reported periods, revenue has moved from US$64.3 million in Q4 2024 to US$65.7 million in Q1 2025, then US$61.1 million in Q2, US$60.2 million in Q3 and US$46.9 million in Q4. Quarterly EPS shifted from roughly a US$0.02 loss in Q4 2024 to a small profit of about US$0.01 in Q1 2025 before returning to losses in the following quarters. For investors watching the path to profitability, the mix of top line scale and still pressured margins keeps attention on how quickly losses might narrow from here.

See our full analysis for LifeMD.

With the headline numbers set, the next step is to see how this earnings report aligns with the widely discussed narratives around LifeMD's growth potential, margin path and overall risk-reward profile.

Losses Narrow On Trailing Basis

• On a trailing 12 month basis, LifeMD reported a basic EPS loss of US$0.32 and net loss of US$14.6 million, compared with a trailing net loss of US$22.0 million a year earlier at US$0.53 loss per share.
• Bullish investors point to the way this shrinking loss lines up with the longer term pattern of losses reducing by 35.2% per year over five years and forecasts for earnings to grow at about 91.73% per year. However, Q4 2025 still showed a US$1.8 million loss despite earlier FY 2025 profitability in Q1.
• The mix of an EPS loss of US$0.04 in Q4 and a small profit of US$0.01 in Q1 2025 shows that the path to consistent profitability is not smooth, even with the trailing improvement.
• The bullish view that profit margins can move from roughly a 3.7% loss today to an 8.1% profit in three years therefore leans heavily on these trend lines, while the quarterly swings in FY 2025 underline the execution risk in getting there.

LifeMD's recent progress on shrinking losses has bulls arguing the story is only just getting started, while the mixed FY 2025 quarters highlight how bumpy that journey can be. 🐂 LifeMD Bull Case

Revenue Growth Versus Profitability Tension

• Trailing 12 month revenue is about US$194.1 million, tied to an 11.2% annual growth rate that sits slightly above the cited 10.3% US market rate, yet LifeMD still reported a trailing loss of US$14.6 million.
• Bears argue that the combination of high customer churn and higher acquisition costs in areas like weight management could keep that 11.2% revenue growth from translating into durable profits. They also point to the FY 2025 pattern, where revenue moved from US$65.7 million in Q1 to US$46.9 million in Q4 alongside a return to quarterly losses after Q1 profitability.
• The cautious narrative highlights that only about one third of cohorts are retained after 12 months, which can make it harder for revenue growth similar to the last year to offset ongoing marketing and operating costs that show up in the continuing net losses.
• At the same time, management having lowered guidance earlier due to pressure in segments like weight management aligns with the idea that even solid top line growth rates may not automatically ease the strain on margins if refund rates and churn remain elevated.

Skeptics see the strong revenue growth figures but focus on whether churn and higher costs in core segments will keep that from meaningfully lifting profitability. 🐻 LifeMD Bear Case

Low P/S Multiple With Volatile Share Price

• At a current share price of US$3.91 and a P/S ratio of 0.9x, LifeMD trades below the US Healthcare Services industry average of 2.2x and below a 1.3x peer average, while the stock has also been more volatile than the broader US market over the last three months.
• The consensus narrative notes that this combination of lower P/S and above market 11.2% revenue growth looks appealing if the company can reach the forecast profitability within three years. However, the current trailing loss of US$14.6 million and recent price volatility indicate that the market is not treating those forecasts as a certainty.
• Analysts reference that LifeMD is expected to move from roughly a 3.7% margin loss today to an 8.1% profit margin in three years, so the current multiple of 0.9x sales is being weighed against that potential margin shift rather than against current earnings.
• For a beginner investor, that means the valuation discount relative to industry averages is tied closely to execution on the earnings path, not simply to the headline revenue growth or the lower multiple in isolation.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for LifeMD on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the combination of shrinking losses and ongoing risks has you undecided, consider taking action now by evaluating both sides of the story for yourself with 3 key rewards and 1 important warning sign.

See What Else Is Out There

LifeMD's mix of ongoing losses, revenue lumpiness and share price volatility shows that earnings quality and risk remain key concerns for investors.

If that volatility and uncertainty around margins has you on edge, consider checking companies in 68 resilient stocks with low risk scores that focus on steadier fundamentals and potentially smoother performance profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.